RT-PCR Gene Expression Panel for Prostate Cancer Survival Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting circulating tumor cells in patients with metastatic castration-resistant prostate cancer are inadequate, particularly in the pre-chemotherapy space, as they fail to detect cells in a significant proportion of patients, limiting the ability to predict overall survival and monitor treatment effects effectively.
Innovation Solution
Development of an RT-PCR platform that analyzes blood samples for the expression of specific genes (KLK3, KLK2, HOXB13, GHRL2, and FOXA1) using specialized collection tubes to stabilize RNA, allowing for reliable prediction of overall survival by detecting two or more transcripts, which is more robust than traditional CTC enumeration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If RT-PCR based detection is used to detect tumor cells in peripheral blood, then detection sensitivity can be improved, but the wide range of results reflects lack of standardization in sample processing and analytical methods
Solution Approach 1:
The patent applies parameter changes by standardizing multiple critical parameters including sample collection timing, RNA stabilization conditions, RT-PCR cycling parameters, and threshold determination criteria. This systematic parameter standardization across all detection steps resolves the inconsistency issue while maintaining high detection sensitivity.
Solution Approach 2:
The patent implements feedback mechanisms through quality control measures including detection of internal controls, verification of RNA integrity, and validation of amplification curves. These feedback loops ensure that only samples meeting predefined quality criteria proceed to analysis, thereby improving result reliability without compromising sensitivity.
2Measurement precision
If CTC detection is performed using CellSearch assay, then detection rates are highest in patients with advanced disease, but survival times for patients with low counts ranged from very short to very long
Solution Approach 1:
The patent applies partial action by detecting a panel of multiple gene transcripts (PSA, PSMA, NKX3.1, HOXB13) rather than relying on a single marker. This approach ensures detection in patients with low CTC counts by increasing the probability that at least one marker will be detectable, thereby improving both detection rate and prognostic reliability across all disease stages.
Solution Approach 2:
The patent uses a composite approach by combining multiple gene expression markers into a single detection platform. This composite marker panel provides more robust prognostic information than single markers, as the combined signal reduces variability and improves predictive accuracy for patient outcomes.
3Loss of information
If PSA mRNA detection is used in patients with no detectable serum PSA, then unique clinical information can be obtained, but the detection rates range widely depending on disease extent
Solution Approach 1:
The patent applies universality by designing a detection platform that functions across all disease stages and PSA levels. The multi-gene panel approach ensures that clinical information can be obtained regardless of serum PSA detectability or disease extent, as different markers have different expression patterns that complement each other across various clinical scenarios.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RT-PCR platform provides a more reliable prediction of poor overall survival and treatment response in patients with metastatic castration-resistant prostate cancer, offering a higher detection frequency and prognostic value compared to existing methods, enabling better clinical decision-making.
Implementation Method 1
an RT-PCR platform to detect gene transcripts
Implementation Method 2
RT-PCR based assay for the messenger RNA (mRNA)
Implementation Method 3
collected in special collection tubes that stabilize intracellular RNA
Data Source
AI summary
Using an RT-PCR platform, detection of gene transcripts highly expressed in prostate tissue and expressed in peripheral blood mononuclear cells (PBMC) from patients with mCRPC can provide a more reliable and robust prediction of poor overall survival than that of CTC enumeration in mCRPC. Disclosed is the identification of five genes, KLK3, KLK2, HOXB13, GHRL2 and FOXA1, the detection of two (2) or more transcripts of which predicts overall poor survival. The test is performed on blood samples that have been collected in collection tubes that stabilize intracellular RNA, require minimal on-site processing and can be easily stored and shipped for subsequent extraction of total RNA from whole blood for RT-PCR.